Type 1 Diabetes

Type 1 Diabetes (T1D) is an autoimmune condition where the pancreas produces little to no insulin. Lifelong management requires careful monitoring of blood glucose levels to prevent acute complications (hypoglycemia/DKA) and long-term organ damage.

• Continuous Glucose Monitoring (CGM): Wearable sensors that provide real-time blood sugar readings, reducing the need for finger pricks and alerting patients to dangerous highs or lows.
• Carbohydrate Counting: Essential for calculating meal-time insulin doses to maintain tight glycemic control.
• Endocrinologist Care: Regular visits to review A1C levels, adjust insulin ratios, and screen for complications (retinopathy, neuropathy, nephropathy).

Because the body cannot produce insulin, exogenous insulin must be administered via injections or pumps.

Insulin Delivery Systems

Multiple Daily Injections (MDI) involve using long-acting basal insulin and rapid-acting bolus insulin for meals. Alternatively, Insulin Pumps deliver rapid-acting insulin continuously, offering more flexibility.

Automated Insulin Delivery (AID) / Closed-Loop Systems

These advanced systems link a CGM directly to an insulin pump. An algorithm automatically adjusts background insulin delivery based on sensor readings, functioning as an "artificial pancreas."

Beyond traditional insulin replacement, researchers are exploring ways to preserve remaining beta cells and address the underlying autoimmunity.

• Disease-Modifying Therapies (Teplizumab): Recently approved for delaying the onset of Stage 3 T1D in high-risk individuals by modulating the immune system's attack on beta cells.
• Islet Cell Transplantation: An experimental procedure where healthy insulin-producing cells from a donor are implanted into the patient's liver, often requiring immunosuppressants.

Researchers are actively testing new interventions to improve care and find a cure. Here are some live trials actively recruiting participants:

• NCT03369821 (University of Exeter): The EXE-T1D study focusing on understanding beta-cell destruction through the study of extremely early-onset Type 1 Diabetes.
• NCT07059806 (Yale University): T1CARE, a randomized trial of a novel intervention to address social determinants of health in young adults with Type 1 Diabetes.
• NCT05610865 (University of the Punjab): Exploring the efficacy of adipose tissue-derived stem cells for the treatment of diabetic foot ulcers.

Because insulin doses are directly tied to food intake, precise dietary management is critical for individuals with Type 1 Diabetes.

• Carbohydrate Counting: This is the most common meal planning technique. Patients learn to estimate the number of grams of carbohydrates in their meals to calculate the exact dose of rapid-acting insulin required to cover the food.
• Insulin-to-Carb Ratio (ICR): A personalized ratio prescribed by an endocrinologist indicating how many grams of carbohydrates are covered by one unit of insulin.
• Glycemic Index (GI): Choosing complex, low-GI carbohydrates (like whole grains, beans, and non-starchy vegetables) helps prevent rapid spikes in blood sugar compared to high-GI foods like sugary drinks and white bread.

Q: What is the difference between Type 1 and Type 2 Diabetes?
A: Type 1 is an autoimmune disease where the body attacks its own insulin-producing cells. Type 2 is a metabolic condition characterized by insulin resistance and relative insulin deficiency, often linked to lifestyle factors.

Q: Can diet and exercise cure Type 1 Diabetes?
A: No. While a healthy diet and regular exercise are crucial for managing blood sugar levels and overall health, they cannot cure T1D or eliminate the need for insulin therapy.

Q: What is an A1C test?
A: The A1C test measures your average blood sugar levels over the past 2-3 months. It provides a broader picture of glycemic control than daily finger pricks.